Journal Of Clinical Oncology[JOURNAL]

Saba NF, Ismaila N, Adkins D … +16 more , Agrawal N, Akhave N, Blomain ES, Cabanillas ME, Chen A, Galloway TJ, Harada G, Li D, Noureldine SI, Scharpf J, Sun LL, Tang M, Wirth L, Worden F, Zandberg DP, Beadle BM

J Clin Oncol · 2026 May · PMID 41921121 · Publisher ↗

UNLABELLED: .. PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Ex... UNLABELLED: .. PURPOSE: To provide evidence-based recommendations on the use of systemic therapy in different types of thyroid cancers. METHODS: The American Society of Clinical Oncology convened a multidisciplinary Expert Panel to evaluate the evidence and formulate recommendations. The literature search included studies published between January 1, 2000, and November 5, 2025, and comprised systematic reviews, meta-analyses, randomized controlled trials, and observational studies. Outcomes of interest included overall survival, disease-free survival, and safety. Expert Panel members used available evidence and informal consensus to develop evidence-based guideline recommendations. RESULTS: A total of 66 publications were identified to inform the evidence base for this guideline. RECOMMENDATIONS: Evidence-based recommendations address the use of systemic therapy in patients with well-differentiated, differentiated high-grade or poorly differentiated, anaplastic, and medullary thyroid cancer.Additional information is available at https://ascopubs.org/topics/asco-guidelines/head-neck-cancer.

Get PDF PubMed ↗

Reply to: Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS.

Johnson ML

J Clin Oncol · 2026 Jun · PMID 41915880 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Treatment Switching and Subsequent Therapy Confound Overall Survival Estimates in PHAROS.

Huang J, Xie ZF

J Clin Oncol · 2026 Jun · PMID 41915879 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Less Isn't Simple: Insights From Postmastectomy Radiotherapy Deintensification Trials.

Mutter RW, Ballman KV

J Clin Oncol · 2026 Mar · PMID 41915878 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Menopausal Hormone Therapy After Breast Cancer: Personalization, Not Prohibition.

Bosserman LD, Dizon DS

J Clin Oncol · 2026 Jun · PMID 41915866 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Beyond Convenience: Does Subcutaneous Pembrolizumab Add Value for Patients and Health Systems?

Teuwen LA, Riechelmann RP, Gyawali B

J Clin Oncol · 2026 Mar · PMID 41915865 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Erratum: Phase I Trial of GD2.CART Cells Augmented With Constitutive Interleukin-7 Receptor for Treatment of High-Grade Pediatric CNS Tumors.

Lin FY, Stuckert A, Tat C … +32 more , White M, Ruggieri L, Zhang H, Mehta B, Lapteva N, Mei Z, Major A, Thakkar S, Shum T, Parikh K, Wu MF, Lindsay HB, Scherer L, Shekar M, Kinnear D, Blessing MM, Baxter P, Wang T, Grilley B, Moeller K, Hicks J, Roy A, Anastas J, Malbari F, Aldave G, Chintagumpala M, Blaney S, Parsons DW, Brenner MK, Heslop HE, Rooney CM, Omer B

J Clin Oncol · 2026 May · PMID 41915864 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy.

Kappadath SC, Kaseb A, Javle M … +2 more , Lam MG, Mahvash A

J Clin Oncol · 2026 Jun · PMID 41911531 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Reply to: Yttrium-90 Radioembolization Provides Durable Local Control and Definitive Radiation Therapy.

Crane CH, Hong TS, Escorcia FE … +1 more , Dawson LA

J Clin Oncol · 2026 Jun · PMID 41911530 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Is Progression-Free Survival 2 Ready for Prime Time in US Food and Drug Administration Regulatory Decision Making?

Fiero MH, Shah M, Amiri-Kordestani L

J Clin Oncol · 2026 Mar · PMID 41911517 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Lu Y

J Clin Oncol · 2026 Jun · PMID 41911510 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Enhancing Delivery of Tobacco Treatment in Oncology Care: Moving the Needle.

Vidrine JI

J Clin Oncol · 2026 Jun · PMID 41911509 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Reply to: Signal Worth Trusting-If We Can Reproduce It: Clarifying Overall Response Rate and Progression-Free Survival in BEACON Immuno.

Gray J, Weston R, Gates S … +1 more , Moreno L

J Clin Oncol · 2026 Jun · PMID 41911507 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Ethical Design and Implementation of Monetary Transfer Interventions in Clinical Cancer Research.

Hantel A, Williams CP, Nipp RD … +4 more , Hanson E, Belle J, Abel GA, Bona K

J Clin Oncol · 2026 Jun · PMID 41894650 · Publisher ↗

Abstract loading — click title to view on PubMed.

Get PDF PubMed ↗

Radiographic Progression With and Without Prostate-Specific Antigen Rise in Patients With Advanced Prostate Cancer Treated With Enzalutamide.

Armstrong AJ, Azad AA, Iguchi T … +8 more , Stenzl A, Mottet N, Russell D, Rosales M, Haas GP, Saad F, Hussain M, Sternberg CN

J Clin Oncol · 2026 May · PMID 41894648 · Full text

PURPOSE: In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate canc... PURPOSE: In patients who received enzalutamide, we characterized the development of radiographic progression (rPD) without prostate-specific antigen (PSA) rise or progression in metastatic hormone-sensitive prostate cancer (mHSPC) and nonmetastatic castration-resistant prostate cancer (nmCRPC). METHODS: We conducted a post hoc analysis in two phase III trials (N = 2,551; ARCHES [ClinicalTrials.gov identifier: NCT02677896]; PROSPER [ClinicalTrials.gov identifier: NCT02003924]) for co-occurrence of rPD ± Prostate Cancer Working Group 2/3-defined PSA progression, and rPD ± any PSA rise from baseline/nadir by treatment. Kaplan-Meier methods were used for overall survival (OS) outcomes. RESULTS: In ARCHES, 3.5% and 8.5% of 574 patients with mHSPC treated with enzalutamide plus androgen-deprivation therapy (ADT) had no PSA rise or PSA progression at rPD, respectively. Of 79 patients with rPD who received enzalutamide plus ADT, 25.3% had no PSA rise and 62.0% did not meet PSA progression criteria compared with 7.4% and 38.3% of 188 patients with rPD treated with ADT alone, respectively. In PROSPER, 4.4% and 10.3% of 933 patients with nmCRPC treated with enzalutamide plus ADT had no PSA rise or PSA progression, respectively, at rPD. However, of 187 patients with rPD who received enzalutamide plus ADT, 21.9% had no PSA rise and 51.3% did not meet PSA progression criteria compared with 3.6% and 18.8% of 224 patients treated with placebo/ADT, respectively. Liver metastases were >5-fold higher in enzalutamide-treated patients with rPD events versus control, although sample size was small. Compared with no rPD, enzalutamide-treated patients with rPD ± PSA rise or progression had worse OS. CONCLUSION: Given the frequent discordance and poor prognosis of imaging-based progression in the absence of PSA changes during enzalutamide treatment in mHSPC and nmCRPC, periodic surveillance using imaging is recommended.

Free PDF PubMed ↗

Phase I Study of Mosperafenib, a Novel Paradox Breaker B-Raf Proto-Oncogene Serine/Threonine Kinase (BRAF) Inhibitor, in Patients With V600-Mutant Solid Tumors.

Vieito M, Fontana E, Han CH … +24 more , Castanon E, Pinato DJ, Bechter O, Eefsen RL, Moreno I, Prenen H, Dummer R, Plummer R, Schnetzler G, Kornacker M, Pettazzoni P, Renner F, About M, Serrano-Serrano ML, Godfried Sie C, Keelara A, Roller A, Dejardin D, Cinato E, Fakolade T, Guarin E, Flinn N, Kratochwil NA, Keshelava N

J Clin Oncol · 2026 May · PMID 41894647 · Publisher ↗

PURPOSE: V600 mutations are tumor-agnostic oncogenic drivers whose targeted inhibition is challenged by therapeutic resistance. Mosperafenib is a novel paradox breaker and brain-penetrant BRAF inhibitor (BRAFi), tested... PURPOSE: V600 mutations are tumor-agnostic oncogenic drivers whose targeted inhibition is challenged by therapeutic resistance. Mosperafenib is a novel paradox breaker and brain-penetrant BRAF inhibitor (BRAFi), tested in this study for safety, maximum tolerated dose (MTD), pharmacokinetics (PK), and preliminary clinical activity. PATIENTS AND METHODS: This phase Ia/b study was conducted in patients with advanced solid tumors harboring a V600 mutation (ISRCTN13713551). The modified continuous reassessment method guided dose escalation of mosperafenib, which was given orally up to 3,600 mg once daily in 28-day cycles. The primary objective was to estimate the MTD and/or recommended phase II dose(s). RESULTS: Eighty patients (60% BRAFi-exposed)-63 with colorectal cancer (CRC), 13 with melanoma, and 4 with other solid tumors-received ≥1 dose of mosperafenib as a single agent for a median of 3.7 months (range, 0.2-28.6). Two dose-limiting grade 3 toxicities of rash and rash maculopapular were reported. MTD was not reached. Grade 3 to 4 treatment-related adverse events (TRAEs) occurred in 13 patients (16.3%); no grade 5 TRAEs events were reported. Two patients (2.5%) discontinued study treatment due to TRAEs. There were no reports of palmar-plantar erythrodysesthesia or keratoacanthoma. Linear and time-independent PK was demonstrated across the tested dose range, achieving exposure levels with sustained PK-derived pERK inhibition ≥90%. An exposure-response relationship was observed. Overall response rate was 24.2%, including two complete responses and 14 partial responses. Median progression-free survival was 6.4 months in patients with CRC (200 mg once daily-1200 mg three times a day) and 3.5 months in patients with melanoma (200 mg once daily-800 mg twice a day). CONCLUSION: Mosperafenib demonstrated a favorable safety profile, sustained target inhibition, and early signs of clinically meaningful single-agent activity in BRAFi-naïve and BRAFi-exposed patients.

Get PDF PubMed ↗